ATE406159T1 - Behandlung von hyperlipidämie - Google Patents

Behandlung von hyperlipidämie

Info

Publication number
ATE406159T1
ATE406159T1 AT02729013T AT02729013T ATE406159T1 AT E406159 T1 ATE406159 T1 AT E406159T1 AT 02729013 T AT02729013 T AT 02729013T AT 02729013 T AT02729013 T AT 02729013T AT E406159 T1 ATE406159 T1 AT E406159T1
Authority
AT
Austria
Prior art keywords
hyperlipidemia
treatment
rar
mammal
inverse agonist
Prior art date
Application number
AT02729013T
Other languages
English (en)
Inventor
Yang-Dar Yuan
Scott Thacher
Elliot Klein
Roshantha Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE406159T1 publication Critical patent/ATE406159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polarising Elements (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
AT02729013T 2001-05-03 2002-04-26 Behandlung von hyperlipidämie ATE406159T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/848,159 US20020193403A1 (en) 2001-05-03 2001-05-03 Methods of treating hyperlipidemia

Publications (1)

Publication Number Publication Date
ATE406159T1 true ATE406159T1 (de) 2008-09-15

Family

ID=25302507

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729013T ATE406159T1 (de) 2001-05-03 2002-04-26 Behandlung von hyperlipidämie

Country Status (7)

Country Link
US (3) US20020193403A1 (de)
EP (2) EP1392284B1 (de)
JP (1) JP2004532239A (de)
AT (1) ATE406159T1 (de)
CA (1) CA2445504A1 (de)
DE (1) DE60228567D1 (de)
WO (1) WO2002089781A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
JP2007518719A (ja) * 2003-12-26 2007-07-12 アラーガン　インコーポレイテッド ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
WO2005093426A2 (en) * 2004-03-26 2005-10-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)
EP1937244B1 (de) 2005-09-30 2018-07-25 Io Therapeutics, LLC Behandlung von krebs mit spezifischen rxr-agonisten
JP2009537540A (ja) * 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ， インコーポレイテッド 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
EP2520561B1 (de) 2007-06-08 2016-02-10 MannKind Corporation IRE-1a-Inhibitoren
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
JP6026024B2 (ja) 2013-06-27 2016-11-16 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
US9877941B2 (en) 2015-10-31 2018-01-30 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
WO2017151833A1 (en) * 2016-03-02 2017-09-08 Smith & Nephew, Inc. Soft tissue repair instruments and method
CN115252789A (zh) 2016-03-10 2022-11-01 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
WO2019241597A1 (en) * 2018-06-14 2019-12-19 Cornell University Compositions and methods for providing cardioprotective effects
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CN115335367B (zh) * 2019-12-19 2024-08-13 奥弗恩制药公司 用于炎性疾病和雄性避孕的RAR-α化合物
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5612356A (en) 1992-12-28 1997-03-18 Eisai Co., Ltd. Heterocycle-containing carbonic acid derivatives
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
US5998654A (en) * 1997-07-25 1999-12-07 Ligand Pharmaceuticals Incorporated Retinoic acid receptor antagonist compounds and methods
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
EP1119350B1 (de) * 1998-10-08 2005-02-23 Allergan, Inc. Rar-antagonisten zur verhütung für männer
US6093838A (en) * 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US11686053B2 (en) 2018-04-13 2023-06-27 Gomaco Corporation Three-dimensional bridge deck finisher

Also Published As

Publication number Publication date
EP1920771A2 (de) 2008-05-14
DE60228567D1 (de) 2008-10-09
EP1392284B1 (de) 2008-08-27
WO2002089781A3 (en) 2003-03-27
EP1920771A3 (de) 2008-07-23
US20020193403A1 (en) 2002-12-19
US20080214652A1 (en) 2008-09-04
JP2004532239A (ja) 2004-10-21
CA2445504A1 (en) 2002-11-14
US20050171151A1 (en) 2005-08-04
EP1392284A2 (de) 2004-03-03
WO2002089781A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DE60228567D1 (de) Behandlung von hyperlipidämie
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60114808D1 (de) Oberflächenbehandlung von medizinischer vorrichtung
FI20012017L (fi) Menetelmä ja laite magneettistimulaation annoslaskentaa varten
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60120276D1 (de) Laserbehandlungsgerät
DE60138597D1 (de) Lumineszente Vorrichtung und dafür verwendete Metallkoordinationsverbindung
NO20034056D0 (no) Proliferative sykdommer
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60132089D1 (de) Vorrichtung zur behandlung von gasen miitels plasma
NO20001870L (no) Ny fremgangsmÕte for behandling
DE60204286D1 (de) Implantierbare vorrichtung
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE366569T1 (de) Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
DE60033020D1 (de) Gerät zur behandlung von zahnkaries
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60103685D1 (de) Behandlung von Poriomania
EP1558238A4 (de) Beta-hydroxyphenylaldylamine und ihre verwendung zur behandlung von glaukom
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties